MedTrace Logo

Three Different Doses of Neostigmine on the Reversal of Cisatracurium-induced Moderate Neuromuscular Blockade

NCT05037006 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2021-09-08

No results posted yet for this study

Summary

The aim of the present study will be to evaluate by means of a prospective randomized clinical trial, the time required for the reversal of moderate neuromuscular blockade (NMB) (Train-of-four count = 3; TOFc 3) to Train-of-four ratio (TOFr) \> 0.9 and TOFr = 1.0 after administration of different doses of neostigmine (30, 50 and 70 mcg/kg) in patients undergoing general anesthesia with propofol or sevoflurane. In addition, the probability of NMB reversal in less than 10 minutes or 15 minutes after neostigmine administration will be registered.

Conditions

  • Neuromuscular Blockade
  • Neuromuscular Blockade, Residual

Interventions

DRUG

Sevoflurane - Neostigmine 30

Neostigmine 30 mcg/kg and atropine 15 mcg/kg when TOFc 3

DRUG

Sevoflurane - Neostigmine 50

Neostigmine 50 mcg/kg and atropine 25 mcg/kg when TOFc 3

DRUG

Sevoflurane - Neostigmine 70

Neostigmine 70 mcg/kg and atropine 35 mcg/kg when TOFc 3

DRUG

TIVA - Neostigmine 30

Neostigmine 30 mcg/kg and atropine 15 mcg/kg when TOFc 3

DRUG

TIVA - Neostigmine 50

Neostigmine 50 mcg/kg and atropine 25 mcg/kg when TOFc 3

DRUG

TIVA - Neostigmine 70

Neostigmine 70 mcg/kg and atropine 35 mcg/kg when TOFc 3

Sponsors & Collaborators

  • Pontificia Universidade Catolica de Sao Paulo

    lead OTHER

Principal Investigators

  • Eduardo T Moro, MD · Pontificia Catholic University of São Paulo

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-10-01
Primary Completion
2021-12-20
Completion
2021-12-20

Countries

  • Brazil

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05037006 on ClinicalTrials.gov